Labor Day

ABBOTT ALERT: Bragar Eagel & Squire, P.C. is Investigating Abbott Laboratories on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, January 20, 2023
Class Action Lawsuit, Professional Services, Legal, Similac, News, Laboratory, Death, Safety, FDA, NYSE, Bacteria, United, Jeanne Eagels, Telephone, Abbott Laboratories, Complaint, US Foods, Labor Day, Infant, P.C, OSHA, Medical device

Our investigation concerns whether the board of directors of Abbott have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Abbott have breached their fiduciary duties to the company.
  • Abbott manufactures various forms of infant formula including formula sold under the brand names Similac, Alimentum, and EleCare.
  • Prior to February 2022, Abbott had produced 40% of the United States’ infant formula.
  • On February 17, 2022, the US Food and Drug Administration (“FDA”) announced it was investigating four consumer complaints of infant illness related to powdered infant formula produced by Abbott Laboratories in Sturgis.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Latch, Azure, Abbott, and TuSimple and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, October 27, 2022
Mission statement, Federal Motor Carrier Safety Administration, Company, LTCH, Death, NASDAQ, Safety, OSHA, Labor Day, IPO, Similac, Bacteria, Azure, Defendant, Abbott Laboratories, Journal, Technology, Culture, US Foods, Travel, Compliance, Complaint, News, GLOBE, FDA, Lists of schools in England, Infant, NYSE, Sale, The Wall Street Journal, Accident, United, Public relations, Pharmaceutical industry, Audit, Medical device, P.C, Latch

On this news, Latchs stock fell $0.13, or 12.2%, to close at $0.95 per share on August 26, 2022, on unusually heavy trading volume.

Key Points: 
  • On this news, Latchs stock fell $0.13, or 12.2%, to close at $0.95 per share on August 26, 2022, on unusually heavy trading volume.
  • For more information on the Azure class action go to: https://bespc.com/cases/AZRE
    Abbott manufactures various forms of infant formula including formula sold under the brand names Similac, Alimentum, and EleCare.
  • For more information on the TuSimple class action go to: https://bespc.com/cases/TSP
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Humanigen, Latch, Azure, and Abbott and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, October 22, 2022
News, Sale, Mission statement, Abbott Laboratories, US Foods, Infant, Cytokine, LTCH, NASDAQ, NYSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Partnership, EUA, OSHA, Food, Emergency Use Authorization, Immune system, Company, Defendant, National, United, Lists of schools in England, Safety, Letter, Bacteria, Complaint, GLOBE, Azure, Similac, P.C, Death, FDA, COVID-19, Labor Day, Pharmaceutical industry, Online gambling, Audit, Medical device, Latch

On this news, Humanigens stock price fell $7.14 per share, or 47.25%, to close at $7.97 per share on September 9, 2021.

Key Points: 
  • On this news, Humanigens stock price fell $7.14 per share, or 47.25%, to close at $7.97 per share on September 9, 2021.
  • Then, on July 13, 2022, Humanigen disclosed that lenzilumab had failed to show statistical significance on the primary endpoint of the ACTIV-5/BET-B study.
  • For more information on the Abbott class action go to: https://bespc.com/cases/ABT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Abbott, TuSimple, Kohl’s, and Bed Bath & Beyond and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, October 17, 2022
News, Culture, SEC, Chewy, Abbott Laboratories, US Foods, Infant, Family, NYSE, NASDAQ, Wall Street, Complaint, IPO, Bed Bath & Beyond, The Wall Street Journal, Federal Motor Carrier Safety Administration, Bed, Insider, Technology, Plan, OSHA, Company, Accident, Defendant, KSS, United, Lists of schools in England, Safety, Bacteria, Journal, GLOBE, Similac, Beauty, Death, Strategic planning, FDA, Bloomberg, Travel, Disclosure, Labor Day, Compliance, Medical device, Audit, Renewable energy, Risk management, Online gambling, P.C, Beyond

For more information on the TuSimple class action go to: https://bespc.com/cases/TSP

Key Points: 
  • For more information on the TuSimple class action go to: https://bespc.com/cases/TSP
    Kohls operates as a retail company in the U.S.
  • On March 25, 2022, Bed Bath & Beyond added three new directors appointed by Ryan Cohens investment firm, RC Ventures LLC.
  • For more information on the Bed Bath & Beyond class action go to: https://bespc.com/cases/BBBY
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Abbott, TuSimple, Kohl’s, and Bed Bath & Beyond and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, October 13, 2022
News, Culture, SEC, Chewy, Abbott Laboratories, US Foods, Infant, Family, NYSE, NASDAQ, Wall Street, Complaint, IPO, Bed Bath & Beyond, The Wall Street Journal, Federal Motor Carrier Safety Administration, Bed, Insider, Technology, Plan, OSHA, Company, Accident, Defendant, KSS, United, Lists of schools in England, Safety, Bacteria, Journal, GLOBE, Similac, Beauty, Death, Strategic planning, FDA, Bloomberg, Travel, Disclosure, Labor Day, Compliance, Medical device, Audit, Renewable energy, Risk management, Online gambling, P.C, Beyond

For more information on the TuSimple class action go to: https://bespc.com/cases/TSP

Key Points: 
  • For more information on the TuSimple class action go to: https://bespc.com/cases/TSP
    Kohls operates as a retail company in the U.S.
  • On March 25, 2022, Bed Bath & Beyond added three new directors appointed by Ryan Cohens investment firm, RC Ventures LLC.
  • For more information on the Bed Bath & Beyond class action go to: https://bespc.com/cases/BBBY
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Azure, Abbott, TuSimple, and Kohl’s and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, October 7, 2022
News, Culture, Abbott Laboratories, US Foods, Infant, Family, NYSE, NASDAQ, Wall Street, Complaint, IPO, The Wall Street Journal, Federal Motor Carrier Safety Administration, Technology, Plan, OSHA, Company, Accident, Defendant, KSS, United, Lists of schools in England, Safety, Bacteria, Journal, GLOBE, State, Azure, Similac, Death, Travel, FDA, Beauty, Disclosure, Labor Day, Compliance, Pharmaceutical industry, Audit, Medical device, Renewable energy, Risk management, P.C

For more information on the Azure class action go to: https://bespc.com/cases/AZRE

Key Points: 
  • For more information on the Azure class action go to: https://bespc.com/cases/AZRE
    Abbott manufactures various forms of infant formula including formula sold under the brand names Similac, Alimentum, and EleCare.
  • For more information on the TuSimple class action go to: https://bespc.com/cases/TSP
    Kohls operates as a retail company in the U.S.
  • For more information on the Kohls class action go to: https://bespc.com/cases/KSS
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Azure, Abbott, TuSimple, and Kohl’s and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, October 3, 2022
Federal Motor Carrier Safety Administration, KSS, GLOBE, OSHA, NASDAQ, Azure, News, Culture, Labor Day, United, Technology, Defendant, The Wall Street Journal, Lists of schools in England, Compliance, IPO, Wall Street, Family, FDA, Abbott Laboratories, Death, Plan, Complaint, Bacteria, Safety, Journal, NYSE, Similac, Strategic planning, Travel, Accident, Disclosure, US Foods, Beauty, Infant, Company, Pharmaceutical industry, Audit, Medical device, Renewable energy, Risk management, P.C

For more information on the Azure class action go to: https://bespc.com/cases/AZRE

Key Points: 
  • For more information on the Azure class action go to: https://bespc.com/cases/AZRE
    Abbott manufactures various forms of infant formula including formula sold under the brand names Similac, Alimentum, and EleCare.
  • For more information on the TuSimple class action go to: https://bespc.com/cases/TSP
    Kohls operates as a retail company in the U.S.
  • For more information on the Kohls class action go to: https://bespc.com/cases/KSS
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Humanigen, Latch, Azure, and Abbott and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, September 27, 2022
National, EUA, Safety, Cytokine, COVID-19, NYSE, FDA, Food, Sale, Infant, United, Company, Similac, News, Partnership, P.C, Patient, Letter, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Complaint, Lists of schools in England, Emergency Use Authorization, Defendant, Bacteria, LTCH, NASDAQ, Death, OSHA, US Foods, GLOBE, Abbott Laboratories, Azure, Immune system, Mission statement, Labor Day, Pharmaceutical industry, Online gambling, Audit, Medical device, Latch

On this news, Humanigens stock price fell $7.14 per share, or 47.25%, to close at $7.97 per share on September 9, 2021.

Key Points: 
  • On this news, Humanigens stock price fell $7.14 per share, or 47.25%, to close at $7.97 per share on September 9, 2021.
  • Then, on July 13, 2022, Humanigen disclosed that lenzilumab had failed to show statistical significance on the primary endpoint of the ACTIV-5/BET-B study.
  • For more information on the Abbott class action go to: https://bespc.com/cases/ABT
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

POSEIDON ACQUISITION CORP. UNILATERALLY INCREASES ITS BID PRICE TO ACQUIRE ALL COMMON SHARES OF ATLAS CORP. NOT CONTROLLED BY ITS MAJORITY SHAREHOLDERS TO $15.50 PER SHARE IN CASH

Retrieved on: 
Monday, September 26, 2022
Professional Services, Finance, United States Department of the Treasury, Labor Day, World Bank, ONE, Danaus, COVID-19, TEU, Atlas Corporation, International Maritime Organization, COSCO, Risk, LIBOR, Hope, Treasury, Contract, Nature, Pressure, Select or special committee (United States Congress), Industry, World, Letter, APR, Solution, Committee, Water, Annual report, Renewable energy, Airline

In an effort to reach a conclusion and bring certainty to Atlas and its shareholders, we are hereby increasing our offer from $14.45 to $15.50 per common share.

Key Points: 
  • In an effort to reach a conclusion and bring certainty to Atlas and its shareholders, we are hereby increasing our offer from $14.45 to $15.50 per common share.
  • We do believe that Atlas shareholders are amenable to a transaction and would want the opportunity to consider this proposal for themselves.
  • It is our hope and preference to work constructively with the Special Committee to allow them to do as such.
  • Inflation remains a key concern to major economies, with the US Labor Departments index reporting consumer price inflation of 8.3% year-on-year for August 2022.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Abbott, TuSimple, Kohl’s, and Sema4 and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, September 22, 2022
Federal Motor Carrier Safety Administration, Workforce, Culture, Safety, Complaint, The Wall Street Journal, Journal, Plan, NYSE, Risk, FDA, Accident, Infant, Beauty, Wall Street, United, Company, Similac, Compliance, KSS, News, P.C, Travel, Lists of schools in England, IPO, Technology, Defendant, Bacteria, Family, Strategic planning, NASDAQ, Death, SMFR, OSHA, Research, GLOBE, US Foods, Abbott Laboratories, Disclosure, Labor Day, Medical device, Audit, Renewable energy, Risk management, Pharmaceutical industry

Abbott manufactures various forms of infant formula including formula sold under the brand names Similac, Alimentum, and EleCare.

Key Points: 
  • Abbott manufactures various forms of infant formula including formula sold under the brand names Similac, Alimentum, and EleCare.
  • For more information on the TuSimple class action go to: https://bespc.com/cases/TSP
    Kohls operates as a retail company in the U.S.
  • For more information on the Sema4 class action go to: https://bespc.com/cases/SMFR
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.